Literature DB >> 20476863

Impaired exercise performance in systemic sclerosis and its clinical correlations.

G Cuomo1, C Santoriello, F Polverino, L Ruocco, G Valentini, M Polverino.   

Abstract

OBJECTIVES: To investigate the prevalence of impaired exercise performance as assessed by a standardized cardiopulmonary exercise test (CPET) in systemic sclerosis (SSc) and to identify the associated disease features.
METHODS: Forty-six SSc patients were enrolled and evaluated for clinical and serological SSc subset, extent of skin and internal organ involvement, and disease activity and severity. Exercise performance was subsequently evaluated in these patients and in 23 healthy individuals matched for sex and age, using a standardized CPET.
RESULTS: Exercise performance, measured by maximum oxygen uptake (VO2 max < 80% of predicted value), was found to be impaired in 43/46 patients. Stepwise regression analysis showed that VO2 max adjusted for body weight VO2 max/kg) was independently correlated with the severity of heart (p = 0.001) and lung (p = 0.013) involvement, left ventricular diastolic dysfunction (p = 0.009), and the Health Assessment Questionnaire Disability Index (HAQ-DI) score (p = 0.016).
CONCLUSIONS: This study demonstrates that physical disability contributes significantly to the development of impaired exercise performance in SSc patients. Cardiopulmonary exercise testing may be included among the battery of tests used to determine the severity of SSc.

Entities:  

Mesh:

Year:  2010        PMID: 20476863     DOI: 10.3109/03009740903555358

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  8 in total

1.  Comparison of physiological responses after incremental shuttle walking test and 6-minute walk test in patients with systemic sclerosis.

Authors:  Buse Ozcan Kahraman; Aylin Tanriverdi; Nazenin Hande Sezgin; Serap Acar; Ahmet Merih Birlik; Aydan Koken Avsar; Bahri Akdeniz; Ebru Ozpelit; Sema Savci
Journal:  Wien Klin Wochenschr       Date:  2022-09-26       Impact factor: 2.275

2.  A prediction model for progressive disease in systemic sclerosis.

Authors:  Jessica Meijs; Anne A Schouffoer; Nina Ajmone Marsan; Theo Stijnen; Hein Putter; Maarten K Ninaber; Tom W J Huizinga; Jeska K de Vries-Bouwstra
Journal:  RMD Open       Date:  2015-12-01

Review 3.  The effect and safety of exercise therapy in patients with systemic sclerosis: a systematic review.

Authors:  Sophie I E Liem; Theodora P M Vliet Vlieland; Jan W Schoones; Jeska K de Vries-Bouwstra
Journal:  Rheumatol Adv Pract       Date:  2019-12-09

4.  Reduced exercise capacity in patients with systemic sclerosis is associated with lower peak tissue oxygen extraction: a cardiovascular magnetic resonance-augmented cardiopulmonary exercise study.

Authors:  Daniel S Knight; Vivek Muthurangu; James T Brown; Tushar Kotecha; Jennifer A Steeden; Marianna Fontana; Christopher P Denton; J Gerry Coghlan
Journal:  J Cardiovasc Magn Reson       Date:  2021-10-28       Impact factor: 5.364

5.  Cardiopulmonary exercise testing and prognosis in patients with systemic sclerosis without baseline pulmonary hypertension: a prospective cohort study.

Authors:  Vasiliki-Kalliopi Bournia; Anastasios Kallianos; Stylianos Panopoulos; Elias Gialafos; Lemonia Velentza; Panayiotis G Vlachoyiannopoulos; Petros P Sfikakis; Georgia Trakada
Journal:  Rheumatol Int       Date:  2021-06-29       Impact factor: 2.631

6.  Exercise capacity in relation to autoantibodies in systemic sclerosis patients.

Authors:  Fujiko Someya; Naoki Mugii; Tetsutarou Yahata; Takao Nakagawa
Journal:  Rheumatol Int       Date:  2012-11-05       Impact factor: 2.631

7.  Physical activity in patients with systemic sclerosis.

Authors:  S I E Liem; J M T A Meessen; R Wolterbeek; N Ajmone Marsan; M K Ninaber; T P M Vliet Vlieland; J K de Vries-Bouwstra
Journal:  Rheumatol Int       Date:  2017-11-18       Impact factor: 2.631

8.  Prognostic value of cardiopulmonary exercise testing in patients with systemic sclerosis.

Authors:  Ralf Ewert; Till Ittermann; Dirk Habedank; Matthias Held; Tobias J Lange; Michael Halank; Jörg Winkler; Sven Gläser; Horst Olschewski; Gabor Kovacs
Journal:  BMC Pulm Med       Date:  2019-11-29       Impact factor: 3.317

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.